ACADIA Pharmaceuticals Inc (FRA:DR6)
€ 13.295 -0.225 (-1.66%) Market Cap: 2.29 Bil Enterprise Value: 1.88 Bil PE Ratio: 83.33 PB Ratio: 4.82 GF Score: 73/100

ACADIA Pharmaceuticals Inc at JMP Securities CNS Forum (Virtual) Transcript

Aug 19, 2020 / 03:00PM GMT
Release Date Price: €32.45 (-1.82%)
Jason Nicholas Butler
JMP Securities LLC, Research Division - MD, Director of Healthcare Research & Equity Research Analyst

Great. Well, thank you, everybody, again for joining us today for the JMP Securities CNS Forum. Really excited to have ACADIA with us next, both Steve Davis, the company's CEO; and Michael Yang, Chief Commercial Officer. Another great first half of the year for NUPLAZID and the on-label indication of Parkinson's disease dementia -- sorry, psychosis. And obviously, a lot of progress with the dementia-related psychosis indication, which you've now submitted the sNDA for.

So maybe -- again, let's just turn it over to you, Steve, for any additional introductory comments, but then would love to just jump in and review how you think the first half of the year went and how you're positioned commercially for the second half of the year with NUPLAZID.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Great. Perfect. Thanks much, Jason. So maybe just to level set, I'll offer a few very brief remarks, and then we'll

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot